Last 29 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -22.07 | — | — | 0.88 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 54.90 | 32.39 | 11.98 | 0.62 | 6.95 | 35.37 | 38.99 | 37.02 | 21.10 | 13.18 | — | 17.19 | 27.84 |
| — | -8.4% | -69.3% | -98.3% | -67.0% | +168.4% | — | +115.3% | -24.2% | -69.7% | — | -73.8% | — | |
| P/B Ratio | 8.59 | 4.47 | 1.98 | 1.13 | 2.75 | 2.98 | 3.10 | 4.45 | 1.48 | 1.01 | 2.47 | 1.66 | 1.97 |
| — | +49.9% | -36.3% | -74.6% | +85.3% | +195.9% | +25.7% | +168.5% | -24.7% | -59.3% | +6.8% | -49.6% | -51.5% | |
| P/FCF | — | — | — | 0.75 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | 0.27 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | 0.28 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Stoke Therapeutics, Inc.'s operating margin was -405.3% in Q3 2025, down 207.7 pp QoQ and up 207.8 pp YoY. This marks the 3rd consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of -148.3% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 9.3% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 90.7% | 100.0% | 100.0% | 100.0% | 100.0% | 77.0% | 73.6% | 56.6% | 63.7% | 147.0% | 77.7% | 64.8% |
| — | -9.3% | +29.8% | +35.9% | +76.6% | +56.9% | -47.6% | -5.3% | -12.5% | -6.6% | +98.3% | -1.8% | — | |
| Operating Margin | -277.3% | -405.3% | -197.6% | 70.2% | -60.4% | -613.1% | -607.4% | -673.0% | -1055.9% | -823.3% | 1340.7% | -479.2% | -831.3% |
| — | +33.9% | +67.5% | +110.4% | +94.3% | +25.5% | -145.3% | -40.4% | -27.0% | +11.9% | +271.6% | +42.0% | — | |
| Net Margin | -243.4% | -360.7% | -170.0% | 71.2% | -46.4% | -540.0% | -531.9% | -625.6% | -962.1% | -741.9% | 1235.6% | -437.6% | -784.8% |
| — | +33.2% | +68.0% | +111.4% | +95.2% | +27.2% | -143.0% | -43.0% | -22.6% | +17.5% | +261.9% | +46.7% | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -45.8% | -11.9% | -6.9% | 39.0% | -4.5% | -11.1% | -13.4% | -17.6% | -16.2% | -13.5% | -15.2% | -11.3% | -13.2% |
| — | -7.1% | +48.9% | +321.7% | +72.0% | +17.6% | +11.6% | -55.5% | -22.9% | -10.9% | -42.9% | -5.0% | -22.8% | |
| ROA | -35.6% | -10.3% | -5.9% | 33.3% | -3.7% | -8.8% | -10.0% | -12.2% | -11.5% | -9.9% | -11.4% | -8.4% | -9.6% |
| — | -17.1% | +40.8% | +373.5% | +67.8% | +11.0% | +12.0% | -45.1% | -19.8% | -9.6% | -42.5% | +5.7% | +3.1% | |
| ROIC | -206.8% | -13.9% | -13.1% | 92.2% | -10.9% | -33.1% | -284.2% | — | — | — | -188.5% | -37.2% | -24.5% |
| — | +58.0% | +95.4% | — | — | — | -50.8% | — | — | — | -1473.5% | -131.9% | -9.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 28.4% YoY to 6.53x, strengthening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | +56.8% | -26.9% | -57.4% | -21.5% | -31.4% | -27.2% | +40.3% | +1.3% | +27.4% | +38.9% | +75.8% | +84.4% | |
| Debt / EBITDA | — | — | — | 0.02 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.81 | 6.53 | 6.98 | 8.41 | 5.81 | 5.09 | 6.67 | 5.43 | 6.99 | 9.13 | 11.28 | 8.57 | 7.77 |
| — | +28.4% | +4.6% | +54.8% | -16.8% | -44.3% | -40.8% | -36.6% | -10.1% | -0.7% | +7.8% | -35.8% | -41.9% | |
| Quick Ratio | 5.81 | 6.53 | 6.98 | 8.41 | 5.81 | 5.09 | 6.67 | 5.43 | 6.99 | 9.13 | 11.28 | 8.57 | 7.77 |
| — | +28.4% | +4.6% | +54.8% | -16.8% | -44.3% | -40.8% | -36.6% | -10.1% | -0.7% | +7.8% | -35.8% | -41.9% | |
| Interest Coverage | — | -14363.67 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 29 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonStoke Therapeutics, Inc.'s current P/E is -22.1x. The average P/E over the last 1 quarters is 0.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Stoke Therapeutics, Inc.'s current operating margin is -277.3%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Stoke Therapeutics, Inc.'s business trajectory between earnings reports.